FIELD: medicine.
SUBSTANCE: method involves applying mono therapy with Cerebrolysin intramuscularly introduced once a day in the morning at a daily dose of 0.1 ml/kg of weight as 20 days long course or Encephabol to be taken 3 times a day in 30 min after having taken meals. Encephabol is given at a dose of 50 mg in 2-5 years old children cases or at a dose of 100 mg in 6-10 years old children cases. Male children take Encephabol in not longer than 10 days long course. Female children take Encephabol in a course being longer than 10 days.
EFFECT: enhanced effectiveness of genome instability adjustment.
6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETERMINING GENOME INSTABILITY IN CHILDREN WITH INFANTILE CEREBRAL PARALYSIS WITH PERIVENTRICULAR LUEKOMALACIA | 2009 |
|
RU2413226C1 |
| METHOD FOR TREATING LOCOMOTIVE, SENSORY AND VOCAL DISORDERS IN CHILDREN AFFECTED WITH HYPERKINETIC AND ATONIC SYNDROMES | 1992 |
|
RU2085197C1 |
| METHOD FOR DETECTING GENOMIC INSTABILITY IN CHILDREN WITH JUVENILE CEREBRAL PALSY | 2005 |
|
RU2295130C1 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2727154C1 |
| METHOD OF TREATMENT OF CHILDREN WITH CONSEQUENCES OF PERINATAL LESION OF CENTRAL NERVOUS SYSTEM BY MEANS OF LYMPHAVIZHINE APPARATUS | 2007 |
|
RU2350359C2 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2727586C1 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2726854C1 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2727162C1 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2727159C1 |
| POLYPEPTIDE COMPOSITION HAVING PROPERTY OF NORMALIZING CEREBRAL FUNCTIONS | 2019 |
|
RU2727167C1 |
